Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (206)	5/19/1999 8:38:00 PM
From: Bob L	Respond to of 666

An ASCO abstract: High Dose Radioiodinated Anti-Cd20 Antibody, Etoposide, Cyclophosphamide and Autologous Transplantation for Patients with Relapsed or Refractory Mantle Cell Lymphoma. asco.org "Mantle cell lymphoma (MCL) is an aggressive variant of non-Hodgkin's lymphoma (NHL) which is incurable with conventional chemotherapy regimens . . . with a median progression free survival of 1 year. . . . We have recently treated five patients . . . . All patients are alive and progression free with a median follow up of 23 months (range 4--29 months). . . ." The "radioiodinated" antibody is Bexxar. This is from the Fred Hutchinson Cancer Center in Seattle, where they seem to be doing a good bit of work with Bexxar and bone marrow/stem cell transplants.